RxDoctor Payments Data

Christopher Baltzell, PA

Physician Assistant · Adel, IANPI 1144776998

Payments from drug & device makers

$3,036in general payments, 2019–2025

Across 189 payments — averaging $16.06 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$996
  • AstraZeneca$257
  • Lilly USA, LLC$241
  • Boehringer Ingelheim$168
  • Sumitomo Pharma America, Inc.$141
  • Pfizer$133
  • plus $1K from 23 others

What the payments were for

  • Food & beverage$3,01399%
  • Education$231%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,036 in reported general payments places this provider in the 90th percentile of 1,140 physician assistant providers in Iowa.

See all physician assistant providers in Iowa

Medicare billing

Part B allowed, 2024
$64,487
Medicare patients
205
Services billed
2,064

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide123$129,433
JardianceEmpagliflozin56$49,189
Tresiba Flextouch U-200Insulin Degludec40$47,146
MounjaroTirzepatide27$34,932
FarxigaDapagliflozin Propanediol34$32,812
EliquisApixaban21$22,182
Trelegy ElliptaFluticasone/Umeclidin/Vilanter19$13,657
JanuviaSitagliptin Phosphate22$11,376
LinzessLinaclotide17$9,447
XareltoRivaroxaban13$9,311
Toujeo SolostarInsulin Glargine,hum.Rec.Anlog18$7,344
Omnipod Dash Pods (Gen 4)Insulin Pump Cart,cont Inf,bt12$6,732
Breo ElliptaFluticasone/Vilanterol13$5,317
FiaspInsulin Aspart (Niacinamide)16$4,442
SavellaMilnacipran Hcl12$2,916

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Fiasp$53$133,876139 claims
Boehringer IngelheimJardiance$168$49,18956 claims
Lilly USA, LLCMounjaro$241$34,93227 claims
AstraZenecaFarxiga$257$32,81234 claims
PfizerEliquis$133$22,18221 claims
GSKTrelegy Ellipta, Breo Ellipta$52$18,97332 claims
AbbVieLinzess, Savella$996$12,36229 claims
MerckJanuvia$24$11,37622 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 1,140 physician assistant providers in Iowa.

Other physician assistant in Adel

See the full list for Iowa

Where these figures come from

Is this you, or does something look wrong? →